| __timestamp | Halozyme Therapeutics, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 100244000 |
| Thursday, January 1, 2015 | 93236000 | 29674000 |
| Friday, January 1, 2016 | 150842000 | 14917000 |
| Sunday, January 1, 2017 | 150643000 | 14118000 |
| Monday, January 1, 2018 | 150252000 | 8737000 |
| Tuesday, January 1, 2019 | 140804000 | 6900000 |
| Wednesday, January 1, 2020 | 34236000 | 6248000 |
| Friday, January 1, 2021 | 35672000 | 12312000 |
| Saturday, January 1, 2022 | 66607000 | 19721000 |
| Sunday, January 1, 2023 | 76363000 | 31283000 |
| Monday, January 1, 2024 | 79048000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. and MannKind Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Halozyme consistently outspent MannKind, with its R&D expenses peaking in 2016 and 2017, reaching nearly double the amount of MannKind's highest expenditure in 2014. However, both companies have shown a downward trend in recent years, with Halozyme's spending dropping by approximately 50% from its peak, while MannKind's expenses have decreased by about 70% since 2014. This divergence in spending strategies highlights the varying priorities and financial strategies within the biotech sector, offering insights into how these companies navigate the challenges of innovation and market competition.
R&D Insights: How Novartis AG and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Pfizer Inc. and MannKind Corporation
Teva Pharmaceutical Industries Limited vs MannKind Corporation: Strategic Focus on R&D Spending
R&D Insights: How Summit Therapeutics Inc. and Halozyme Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
Research and Development Investment: Halozyme Therapeutics, Inc. vs PTC Therapeutics, Inc.
Research and Development Investment: Halozyme Therapeutics, Inc. vs Veracyte, Inc.
Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Verona Pharma plc and MannKind Corporation Allocate Funds
R&D Spending Showdown: Perrigo Company plc vs MannKind Corporation
Research and Development Investment: Vericel Corporation vs MannKind Corporation
R&D Insights: How MannKind Corporation and Taro Pharmaceutical Industries Ltd. Allocate Funds